CYP19A1 and polycystic ovary syndrome: With these premises and in light of the observation that DCIns reduces aromatase expression in human granulosa cells [32], we hypothesized that, similarly to the effects of the aromatase inhibitor letrozole, the administration of DCIns alone at high doses to normal female mice would result in the production of an androgenic PCOS-like model or other ovarian lesions.